DURHAM, N.C. - Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced today the appointment of Marc D. Kozin as the newest member of its Board of Directors. Concurrently, the company disclosed the retirement of Patrick Machado from the board, effective at the June 2024 Annual Meeting of Stockholders, marking the end of his ten-year tenure.
Mike Andriole, Chief Executive Officer of Chimerix, expressed his optimism about Kozin's addition to the board and gratitude towards Machado for his decade of service. Kozin's extensive experience in corporate strategy, particularly in life sciences, is expected to support Chimerix's strategic growth and the advancement of its clinical pipeline.
Kozin has over 35 years of experience in corporate and business strategy, mergers and acquisitions, and value management. He previously served as President of L.E.K. Consulting, where he played a pivotal role in the firm's life science strategic planning practice. He holds a B.A. in Economics from Duke University and an M.B.A. from The Wharton School, University of Pennsylvania. Kozin is also on the Board of Directors of UFP Technologies (NASDAQ: UFPT) and HCRx Holdings.
Chimerix's primary focus is on developing medications to significantly improve and prolong the lives of patients with deadly diseases. The company's most advanced clinical-stage development program, ONC201, targets H3 K27M-mutant glioma, a form of brain cancer.
The company cautions that this press release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from those projected. These statements reflect the company's current views and are subject to change. Chimerix disclaims any intent or obligation to update these forward-looking statements.
The information for this article is based on a press release statement from Chimerix, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.